Cargando…

Buprenorphine Waiver Attitudes Among Primary Care Providers

BACKGROUND: Despite efforts to improve access to Medications for Opioid Use Disorder (MOUD), such as buprenorphine, the number of opioid overdoses in the United States continues to rise. In April 2021, the Department of Health and Human Services removed the mandatory training requirement to obtain a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Benjamin, Croghan, Ivana, Ebbert, Jon O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284198/
https://www.ncbi.nlm.nih.gov/pubmed/35822763
http://dx.doi.org/10.1177/21501319221112272
_version_ 1784747511426056192
author Lai, Benjamin
Croghan, Ivana
Ebbert, Jon O.
author_facet Lai, Benjamin
Croghan, Ivana
Ebbert, Jon O.
author_sort Lai, Benjamin
collection PubMed
description BACKGROUND: Despite efforts to improve access to Medications for Opioid Use Disorder (MOUD), such as buprenorphine, the number of opioid overdoses in the United States continues to rise. In April 2021, the Department of Health and Human Services removed the mandatory training requirement to obtain a buprenorphine waiver; the goal was to encourage more providers to prescribe buprenorphine, thus improving access. Little is known about the attitudes on buprenorphine prescribing after this policy change. OBJECTIVE: The primary objective was to assess attitudes among primary care providers toward the removal of the buprenorphine waiver training requirement. A secondary objective was to identify other barriers to prescribing buprenorphine. METHODS: We conducted a survey between September 15 and October 13, 2021 to assess the overall beliefs on the effectiveness of MOUD and attitudes toward the removal of the waiver training, current knowledge of buprenorphine, current practice styles related to screening for and treating OUD, and attitudes toward prescribing buprenorphine in the future. This survey was sent to 890 Mayo Clinic primary care providers in 5 US states. RESULTS: One hundred twenty-three respondents (13.8%) completed the survey; 35.8% respondents agreed that the removal of the waiver training was a positive step. These respondents expressed a greater familiarity with the different formulations, pharmacology, and titration of buprenorphine. This group was also more likely to prescribe (or continue to prescribe) buprenorphine in the future. Approximately one-third (34.4%) of respondents reported perceived institutional support in prescribing buprenorphine. This group expressed greater confidence in diagnosing OUD, had greater familiarity with the different formulations, pharmacology, and titration of buprenorphine, and was more likely to prescribe (or continue to prescribe) buprenorphine in the future. Respondents who have been in practice for 11 to 20 years since completion of training were most likely to refer all OUD patients to specialists. CONCLUSIONS: Results of our survey suggests that simply removing the mandatory waiver training requirement is insufficient in positively changing attitudes toward buprenorphine prescribing. A key barrier is the perceived lack of institutional support. Future studies investigating effective ways to provide such support may help improve providers’ willingness to prescribe buprenorphine.
format Online
Article
Text
id pubmed-9284198
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-92841982022-07-16 Buprenorphine Waiver Attitudes Among Primary Care Providers Lai, Benjamin Croghan, Ivana Ebbert, Jon O. J Prim Care Community Health Original Research BACKGROUND: Despite efforts to improve access to Medications for Opioid Use Disorder (MOUD), such as buprenorphine, the number of opioid overdoses in the United States continues to rise. In April 2021, the Department of Health and Human Services removed the mandatory training requirement to obtain a buprenorphine waiver; the goal was to encourage more providers to prescribe buprenorphine, thus improving access. Little is known about the attitudes on buprenorphine prescribing after this policy change. OBJECTIVE: The primary objective was to assess attitudes among primary care providers toward the removal of the buprenorphine waiver training requirement. A secondary objective was to identify other barriers to prescribing buprenorphine. METHODS: We conducted a survey between September 15 and October 13, 2021 to assess the overall beliefs on the effectiveness of MOUD and attitudes toward the removal of the waiver training, current knowledge of buprenorphine, current practice styles related to screening for and treating OUD, and attitudes toward prescribing buprenorphine in the future. This survey was sent to 890 Mayo Clinic primary care providers in 5 US states. RESULTS: One hundred twenty-three respondents (13.8%) completed the survey; 35.8% respondents agreed that the removal of the waiver training was a positive step. These respondents expressed a greater familiarity with the different formulations, pharmacology, and titration of buprenorphine. This group was also more likely to prescribe (or continue to prescribe) buprenorphine in the future. Approximately one-third (34.4%) of respondents reported perceived institutional support in prescribing buprenorphine. This group expressed greater confidence in diagnosing OUD, had greater familiarity with the different formulations, pharmacology, and titration of buprenorphine, and was more likely to prescribe (or continue to prescribe) buprenorphine in the future. Respondents who have been in practice for 11 to 20 years since completion of training were most likely to refer all OUD patients to specialists. CONCLUSIONS: Results of our survey suggests that simply removing the mandatory waiver training requirement is insufficient in positively changing attitudes toward buprenorphine prescribing. A key barrier is the perceived lack of institutional support. Future studies investigating effective ways to provide such support may help improve providers’ willingness to prescribe buprenorphine. SAGE Publications 2022-07-13 /pmc/articles/PMC9284198/ /pubmed/35822763 http://dx.doi.org/10.1177/21501319221112272 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Lai, Benjamin
Croghan, Ivana
Ebbert, Jon O.
Buprenorphine Waiver Attitudes Among Primary Care Providers
title Buprenorphine Waiver Attitudes Among Primary Care Providers
title_full Buprenorphine Waiver Attitudes Among Primary Care Providers
title_fullStr Buprenorphine Waiver Attitudes Among Primary Care Providers
title_full_unstemmed Buprenorphine Waiver Attitudes Among Primary Care Providers
title_short Buprenorphine Waiver Attitudes Among Primary Care Providers
title_sort buprenorphine waiver attitudes among primary care providers
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284198/
https://www.ncbi.nlm.nih.gov/pubmed/35822763
http://dx.doi.org/10.1177/21501319221112272
work_keys_str_mv AT laibenjamin buprenorphinewaiverattitudesamongprimarycareproviders
AT croghanivana buprenorphinewaiverattitudesamongprimarycareproviders
AT ebbertjono buprenorphinewaiverattitudesamongprimarycareproviders